Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

1.87
+0.02001.08%
Post-market: 1.870.00000.00%19:43 EDT
Volume:35.97K
Turnover:66.85K
Market Cap:10.23M
PE:-0.08
High:1.91
Open:1.80
Low:1.80
Close:1.85
Loading ...

BRIEF-BioXcel Therapeutics Increases Board Size To Eight Directors

Reuters
·
16 Jan

BioXcel Therapeutics Inc - Increases Board Size to Eight Directors

THOMSON REUTERS
·
16 Jan

BioXcel Therapeutics files to sell 5.1M shares of common stock for holders

TIPRANKS
·
11 Jan

BioXcel Therapeutics Inc Files for Resale of up to 5.1 Mln Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
11 Jan

BofA Securities Downgrades BioXcel Therapeutics to Underperform From Buy, Adjusts Price Target to $0.25 From $7

MT Newswires Live
·
07 Jan

BioXcel Therapeutics Inc : Bofa Global Research Cuts to Underperform From Buy; Cuts Price Objective to $0.25 From $7

THOMSON REUTERS
·
07 Jan

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

Zacks
·
24 Dec 2024

BioXcel Therapeutics prices 5.6M shares at 48c in public offering

TIPRANKS
·
22 Nov 2024

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

THOMSON REUTERS
·
22 Nov 2024

BRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations

Reuters
·
22 Nov 2024

BRIEF-Bioxcel Therapeutics Announces Proposed Public Offering

Reuters
·
22 Nov 2024

BioXcel Therapeutics Announces Proposed Public Offering

THOMSON REUTERS
·
22 Nov 2024

BioXcel Therapeutics- as of Nov 18, ‘431 Patent Has Been Accepted for Listing in FDA Approved Drug Products With Therapeutic Equivalence Evaluations

THOMSON REUTERS
·
22 Nov 2024

Bank of America Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)

TIPRANKS
·
15 Nov 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

GuruFocus.com
·
15 Nov 2024

Q3 2024 BioXcel Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
15 Nov 2024

BioXcel Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
14 Nov 2024

BioXcel Therapeutics Q3 Basic EPS USD -0.32 VS. Ibes Estimate USD -0.54

THOMSON REUTERS
·
14 Nov 2024

BioXcel Therapeutics Q3 Operating Expenses USD 15.507 Million

THOMSON REUTERS
·
14 Nov 2024